Francis Medical is developing the Vanquish® Water Vapor Ablation System, which utilizes thermal energy from sterile water vapor to ablate cancerous prostate tissue through a minimally invasive transurethral procedure. This technology aims to reduce the severe side effects associated with traditional prostate cancer treatments, allowing patients to return to their normal activities the day after the procedure.
Funding
$160M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SBFounders
Product
Problem
Existing prostate cancer treatments often lead to significant side effects such as urinary incontinence and erectile dysfunction, impacting patients' quality of life. Traditional methods may also require extended hospital stays and recovery periods.
Solution
Francis Medical is developing the Vanquish Water Vapor Ablation System, a minimally invasive therapeutic solution for prostate cancer. The system uses thermal energy from sterile water vapor to ablate cancerous prostate tissue through a transurethral procedure. This targeted approach aims to reduce the likelihood of life-altering side effects associated with conventional treatments. The Vanquish system is designed to protect surrounding structures during ablation, and patients may be able to return home and resume normal activities shortly after the procedure.
Target Audience
The primary target audience includes urologists and patients seeking less invasive prostate cancer treatments with fewer side effects compared to traditional methods.
Features
- Transurethral delivery of sterile water vapor for targeted ablation of prostate cancer tissue
- Designed to protect surrounding structures to minimize side effects
- Minimally invasive procedure, potentially reducing hospital stays
- Focus on prostate cancer treatment, with potential applications for kidney and bladder cancers